BioXcel Therapeutics, Inc. (BTAI) Company Total Revenue

The use of AI for drug repositioning is driving growth, as evidenced by BioXcel Therapeutics (BTAI) sales figures. The 0.00 level reflects the current magnitude of this trend. The foundation of this success is based on the implementation of Igalmi for global neurology reach, while a digital platform provides a competitive edge by exponentially accelerating the search for therapeutic solutions compared to the classical approach.

BTAI - BioXcel Therapeutics, Inc. Company Revenue over the range 07/04/2022 - 09/19/2026

Analytical breakdowns for BioXcel Therapeutics, Inc. (BTAI)

- share price and expert price forecast:

Price Performance Chart BioXcel Therapeutics Corp|BTAI - Price Target Chart

- market capitalization details:

Market Value BioXcel Therapeutics, Inc.|BTAI - Total Company Value

- book value of equity indicators:

Net Assets per Single Share BioXcel Therapeutics|BTAI - Company Book Value|Market-to-Book Ratio bioxceltherapeutics.com|BTAI - Company Total Assets

- company liabilities and liquidity data:

Debt to Capital Ratio BioXcel Therapeutics|BTAI - Long-Term Debt to Equity Ratio|Current Liabilities to Capital BioXcel Therapeutics Inc|BTAI - Company Aggregate Debts|Debt to Book Capitalization Ratio BioXcel Therapeutics, Inc.|BTAI - Company Long-Term Debts|Short-Term Debt Volume BioXcel Therapeutics|Immediate Liquidity bioxceltherapeutics.com

- earnings and market ratios statistics:

BTAI - Net Income|Net Profit Forecast BioXcel Therapeutics|BTAI - P/E Multiple|Projected Price to Earnings bioxceltherapeutics.com|BTAI - PEG Multiple|Company Value to EBITDA BioXcel Therapeutics, Inc.|BTAI - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months BioXcel Therapeutics|BTAI - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months bioxceltherapeutics.com|BTAI - Net earnings per share growth this year|Projected earnings per share increase next year BioXcel Therapeutics

- sales volume and revenue indicators:

BTAI - Revenue and Sales Volume|Company Future Revenue BioXcel Therapeutics Corp|BTAI - P/S Multiple|Market Cap to Future Revenue Ratio BioXcel Therapeutics, Inc.

Summary company analysis:BioXcel Therapeutics Corp

Mass-produced product of BioXcel Therapeutics

This metric captures the actual cash inflow from product sales, reflecting the efficiency of the business's operating cycles. It serves as an indicator of financial stability, where a decline in inflows signals a risk of frozen capital. For BioXcel Therapeutics (BTAI), this is critical due to liquidity shortages and the expansion of low-cost generics during the drug's market launch. By analyzing the sales volume dynamics of BioXcel Therapeutics (BTAI), an investor can assess the viability of the commercial strategy.

Key competitors